This page shows the latest CSCC news and features for those working in and with pharma, biotech and healthcare.
The drug is the first and only systemic treatment option available for CSCC patients in England. ... NICE’s decision was based on positive results from the EMPOWER-CSCC-1 trial.
Another is Libtayo (cemiplimab), its latecomer checkpoint inhibitor which has however the first drug in the PD-1/PD-L1 class to be approved for cutaneous squamous cell carcinoma (CSCC), a
squamous cell carcinoma (CSCC). The Regeneron-partnered drug is the first drug in the checkpoint inhibitor class to get a green light in that type of skin cancer, and is also
It could also provide a leap forward for Libtayo, which was approved for cutaneous squamous cell carcinoma (CSCC) in the US in 2018 and in Europe earlier this year, but is
carcinoma (CSCC) in June. ... Regeneron books sales of Libtayo in the US, where it was approved for CSCC last year, and made $68m from the drug in the first half of the year.
It is too soon to gauge the take-up of Sanofi’s new cancer immunotherapy Libtayo (cemiplimab), which has just been approved for cutaneous squamous cell carcinoma (CSCC) in Europe after
More from news
Approximately 3 fully matching, plus 14 partially matching documents found.
EXCELLENCE IN MULTICHANNEL COMMUNICATIONS. ASCENT: Actioning CSCC (cutaneous squamous-cell carcinoma) Education and Navigating Treatment Pathways.
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
OncoSec is a clinical-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target...